$21.01
1.94% yesterday
Nasdaq, Aug 12, 10:00 pm CET

Fulgent Genetics Stock price

$21.01
+1.89 9.88% 1M
+4.79 29.53% 6M
+2.54 13.75% YTD
-2.83 11.87% 1Y
-31.40 59.91% 3Y
-20.62 49.53% 5Y
+11.83 128.87% 10Y
+11.83 128.87% 20Y
Nasdaq, Closing price Tue, Aug 12 2025
+0.40 1.94%

Key metrics

Basic
Market capitalization
$630.9m
Enterprise Value
$340.9m
Net debt
positive
Cash
$292.9m
Shares outstanding
30.6m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
2.1 | 2.0
EV/Sales
1.1 | 1.1
EV/FCF
negative
P/B
0.6
Financial Health
Equity Ratio
92.9%
Return on Equity
-3.8%
ROCE
-6.4%
ROIC
-7.4%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$303.2m | $316.9m
EBITDA
$-64.8m | $-24.2m
EBIT
$-72.7m | $-70.8m
Net Income
$-51.0m | $-17.2m
Free Cash Flow
$-60.0m
Growth (TTM | estimate)
Revenue
4.3% | 11.8%
EBITDA
64.7% | 63.4%
EBIT
62.0% | 4.2%
Net Income
68.8% | 59.8%
Free Cash Flow
-610.2%
Margin (TTM | estimate)
Gross
40.0%
EBITDA
-21.4% | -7.6%
EBIT
-24.0%
Net
-16.8% | -5.4%
Free Cash Flow
-19.8%
More
EPS
$-1.7
FCF per Share
$-2.0
Short interest
11.2%
Employees
1k
Rev per Employee
$220.0k
Show more

Is Fulgent Genetics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Fulgent Genetics Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Fulgent Genetics forecast:

6x Buy
67%
3x Hold
33%

Analyst Opinions

9 Analysts have issued a Fulgent Genetics forecast:

Buy
67%
Hold
33%

Financial data from Fulgent Genetics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
303 303
4% 4%
100%
- Direct Costs 182 182
3% 3%
60%
121 121
7% 7%
40%
- Selling and Administrative Expenses 136 136
5% 5%
45%
- Research and Development Expense 50 50
6% 6%
16%
-65 -65
65% 65%
-21%
- Depreciation and Amortization 7.97 7.97
0% 0%
3%
EBIT (Operating Income) EBIT -73 -73
62% 62%
-24%
Net Profit -51 -51
69% 69%
-17%

In millions USD.

Don't miss a Thing! We will send you all news about Fulgent Genetics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Fulgent Genetics Stock News

Positive
The Motley Fool
11 days ago
Fulgent (FLGT) Q2 Revenue Jumps 16%
Positive
The Motley Fool
11 days ago
Friday's stock market was generally a gloomy place, but apparently someone forgot to tell Fulgent Genetics (FLGT 7.80%). The company's shares were soaring in late-session action, with a very healthy rise of more than 8%.
Neutral
Seeking Alpha
11 days ago
Fulgent Genetics, Inc. (NASDAQ:FLGT ) Q2 2025 Earnings Conference Call August 1, 2025 8:30 AM ET Company Participants Brandon Perthuis - Chief Commercial Officer Ming Hsieh - Chairman & CEO Paul Kim - Chief Financial Officer Conference Call Participants Andrew Harris Cooper - Raymond James & Associates, Inc., Research Division David Michael Westenberg - Piper Sandler & Co., Research Division Lu...
More Fulgent Genetics News

Company Profile

Fulgent Genetics, Inc. operates as a technology company, which provides genetic testing and next generation sequencing solutions. Its technology platform includes proprietary gene probes, advanced database algorithms, adaptive learning software, and proprietary laboratory information management systems. The company was founded on May 13, 2016 and is headquartered in Temple City, CA.

Head office United States
CEO Ming Hsieh
Employees 1,313
Founded 2016
Website www.fulgentgenetics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today